The stock of Kitov Pharma Ltd (NASDAQ:KTOV) has been Upgraded to Buy from Neutral by H.C. Wainwright in its latest research note that was published on November 21. KTOV was given a price target of$10 by H.C. Wainwright, with other Wall Street analysts also giving their reports regarding the stock. Rodman & Renshaw, analysts launched coverage of KTOV stock with a Buy rating, according to their flash note to investors on February 16.
Kitov Pharma Ltd, which has current market capitalization of above $14 Million, published its last quarter earnings on December 31, 2018.
KTOV surged by $0.09 during the normal trading session on Tuesday and reaching a high of $0.79 during the day while it closed the day at $0.73. The Kitov stock had a low trading volume of 0.15 million shares on that day, which is low compared to the average daily volume of 106.73M shares. KTOV has also lost 1.73% of its value over the past 7 days. However, the stock has declined by 29.96% in the 3 months of the year. Over the past six months meanwhile, it has lost 36.98% while it has added 10.18% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -32.67% from its 3 months high price. However, taking another look at KTOV will indicate that it is trading +6.75% away from its 90-day low. Looking at the bigger picture, the Kitov Pharma Ltd stock has dropped by -75.1% from its 52-week high while it has surged by +29.86% from its 52-week low price.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 11.53%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 14.9%. Over the past 20 days, Kitov’s Stochastic %K stood at 7.98% while its Stochastic %D was revealed to be 5.38%.